169 related articles for article (PubMed ID: 37658148)
21. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma.
Knezevich SR; Hendson G; Mathers JA; Carpenter B; Lopez-Terrada D; Brown KL; Sorensen PH
Hum Pathol; 1998 Mar; 29(3):289-94. PubMed ID: 9496833
[TBL] [Abstract][Full Text] [Related]
22. Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Reed DR; Grohar P; Rubin E; Binitie O; Krailo M; Davis J; DuBois SG; Janeway KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30583. PubMed ID: 37501549
[TBL] [Abstract][Full Text] [Related]
23. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
[TBL] [Abstract][Full Text] [Related]
24. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
25. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
26. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
27. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
29. Congenital Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature.
Jin SG; Jiang XP; Zhong L
Pediatr Neonatol; 2016 Oct; 57(5):436-439. PubMed ID: 24480101
[TBL] [Abstract][Full Text] [Related]
30. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
31. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
32. Primary uterine Ewing sarcoma - A case report.
Wu YC; Kao YC; Chang CW
Taiwan J Obstet Gynecol; 2021 Jan; 60(1):142-144. PubMed ID: 33494989
[TBL] [Abstract][Full Text] [Related]
33. Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor in the Adrenal Gland of a Child.
Goudarzipour K; Farahmandi F; Mohammadi A; Taherian R
Iran J Kidney Dis; 2018 May; 12(3):190-192. PubMed ID: 29891750
[TBL] [Abstract][Full Text] [Related]
34. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma.
Haveman LM; van Ewijk R; van Dalen EC; Breunis WB; Kremer LC; van den Berg H; Dirksen U; Merks JH
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011405. PubMed ID: 34472082
[TBL] [Abstract][Full Text] [Related]
36. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
37. Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney.
Risi E; Iacovelli R; Altavilla A; Alesini D; Palazzo A; Mosillo C; Trenta P; Cortesi E
Urology; 2013 Aug; 82(2):382-6. PubMed ID: 23800653
[TBL] [Abstract][Full Text] [Related]
38. Study of EWS/FLI-1 rearrangement in 18 cases of CK20+/CM2B4+ Merkel cell carcinoma using FISH and correlation to the differential diagnosis of Ewing sarcoma/peripheral neuroectodermal tumor.
Fernandez-Flores A; Suarez-Peñaranda JM; Alonso S
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):379-85. PubMed ID: 23165331
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.
Kelleher FC; Thomas DM
Clin Sarcoma Res; 2012 Feb; 2(1):6. PubMed ID: 22587874
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of human Ewing/PNET sarcoma models.
Teicher BA; Bagley RG; Rouleau C; Kruger A; Ren Y; Kurtzberg L
Ann Saudi Med; 2011; 31(2):174-82. PubMed ID: 21422656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
